Hoyer on pharmaceutical strategy: Confidential reimbursement amounts will be at the expense of those paying contributions.
13.12.2023 15:49
The cabinet has approved the federal government's pharmaceutical strategy. The package of measures includes, among other things, allowing pharmaceutical companies to disclose confidential reimbursement amounts and maintaining the manufacturer's discount for reimbursable drugs without a fixed price at the current level of 7 percent. Jens Martin Hoyer, Deputy Chairman of the Board of the AOK Federal Association, commented:
„"Accelerated approval processes, accelerated digitalization, systematic research facilitation, and deregulation are certainly effective levers for strengthening Germany's position as a pharmaceutical hub and its capacity for innovation. However, all of this must not be used to undermine legitimate transparency requirements in pricing and at the expense of those who pay contributions.".
The planned confidential reimbursement prices will further strain the liquidity of statutory health insurance and drive up drug prices in Germany. The permanent reduction of the manufacturer's discount will also place an additional burden on contributors without improving healthcare.“